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What's new? 
 Quality of life (QoL) is a multidimensional, subjective and dynamic construct that is recognized 
as an important outcome in its own right.  
 It remains a challenge to assess the impact of diabetes on QoL with a standardized tool, balancing 
comprehensiveness, subjectivity and brevity. 
 Monitoring well-being and providing psychological care is recommended in diabetes guidelines, 
but there is no recommendation to assess QoL or guidance on how to assess this.   
 This review highlights several gaps in research and clinical practice, which need to be addressed 
if we are to improve the QoL of people with diabetes. 
 
Abstract 
Over the past 25 years, there has been significant acknowledgement of the importance of assessing the 
impact of diabetes on quality of life. Yet, despite the development of several diabetes-specific quality-
of-life measures, the challenges we faced in 1995 remain. There is little consensus on the definition of 
quality of life because of the complexity and subjectivity of the concept. General quality of life 
comprises several domains of life, and these are highly individualized. Assessing the impact of 
diabetes on these life domains adds to the complexity. While comprehensive diabetes-specific quality-
of-life measures typically increase respondent burden, brief questionnaires may not capture all 
relevant/important domains. Today, the lack of resolution of these challenges may explain why the 
impact of diabetes on quality of life is not systematically assessed in research or clinical care.  Few 
researchers report detailed rationales for assessment, there is often a mismatch between the concept of 
interest and the measure selected, and data are misinterpreted as assessing the impact of diabetes on 
quality of life when, in reality, related but distinct constructs have been assessed, such as diabetes 
distress, treatment satisfaction or health status. While significant efforts are being made to increase 
routine monitoring of psychological well-being and understand the lived experience, no guidelines 
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consensus on which questionnaire(s) to use. The gaps identified in this review need urgent attention, 
starting with recognition that assessment of diabetes-specific quality of life is as important as 
biomedical markers, if we are to improve the lives of people with diabetes.  
 
Introduction 
 The shoe that fits one person pinches another;  
there is no recipe for living that suits all cases  
(Carl Jung) 
Living with diabetes requires life-long self-care, demanding a high commitment from the individual if 
both long-term health and quality of life (QoL) are to be protected. In this context, QoL is the ultimate 
goal. However, the demands of diabetes self-management do not sit easily with the unpredictable and 
high-paced nature of modern life. Indeed, there is often a conflict between what is required for optimal 
daily diabetes self-management and optimal daily QoL. While health professionals focus on the long-
term benefits of maintaining optimal glucose levels, most people with diabetes are 'more concerned 
about the immediate demands of intensive treatment and tend to lose sight of possible future benefits' 
[1]. So, protecting QoL is not only the ultimate goal but also a daily goal, and one that can conflict 
directly with biomedical goals. In a society increasingly focused on instant gratification, we 
continually ask people with diabetes to subscribe to delayed gratification, sacrificing today’s QoL for 
the promise of tomorrow’s. However, it is not a promise and it is not tomorrow. It is a hope that 
managing diabetes carefully over many, many years will ultimately result in nothing—no 
complications—just life as other people without diabetes might reasonably expect. Therefore, to 
ensure that interventions are tailored to suit the individual and protect what matters to them, we need 
to value and assess the impact of diabetes and its treatment on QoL. Most people have some sense that 
QoL is important and, intuitively, have some understanding of what it means to them. Therein lies 
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In this review, we present a brief history of how the impact of diabetes on QoL has been 
conceptualized and operationalized, identifying ongoing challenges in its measurement in research and 
clinical practice. We describe and critique a selection of generic and diabetes-specific measures, which 
were either designed with the intention of assessing the impact of diabetes on QoL or have been 
interpreted as doing so in landmark studies and, therefore, represent key developments over the past 
25 years.  
 
What we knew in 1995  
Many measures have been developed to assess quality of life.  
The strategies underlying these measures vary considerably 
(The DCCT Research Group [2]) 
Theoretical exploration of the concept of QoL began in the mid-20th century and reflects a number of 
intersecting phenomena: the rise of the biopsychosocial model [3]; the rise of the ‘patient’ as an active 
‘consumer’ of healthcare; and the changing face of global health. The demise of acute conditions and 
the growth of an aging population with long-term conditions required a focus not so much on ‘cure’, 
but on living well [4]. In this climate, interest in QoL assessment expanded rapidly 'as a valid indicator 
of whether or not a medical treatment is beneficial' [5], but universally accepted definitions remained 
elusive. It may seem obvious that QoL is a personal evaluation of how good or bad one’s life is [6], 
but attempts to agree a more operational definition have had limited success. For some, QoL is the 
degree to which human needs (e.g. health, mobility, food, shelter) are met [7]. For others, it is clear 
that having one’s basic needs met does not equate to a quality life: a ‘life worth living’. Alternatively, 
Calman’s ‘expectations model’ (known as ‘Calman’s Gap’) suggests that QoL is the difference 
between an individual’s hopes and/or expectations and their current experience [8]. This definition has 
inherent appeal, as it is concerned with an individual’s own assessment of what he/she wants from life 
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A tale of two studies: the impact of diabetes treatment intensification on quality of life 
Developed in the late 1980s for inclusion in the landmark Diabetes Control and Complications Trial 
(DCCT), the Diabetes Quality of Life (DQOL) questionnaire [2] was the first measure to assess 
diabetes-specific QoL. The DCCT Research Group noted that 'because intensive treatment would 
carry additional demands… it was anticipated that this might affect the quality of life of patients' [9]. 
Designed 'to address patient-perceived personal burden of the trial' [2], the DQOL includes four scales 
(Satisfaction, Impact, Diabetes Worry, Social/Vocational Worry). The DCCT terminated early, with 
overwhelming evidence favouring the benefits of intensive insulin therapy for the prevention of 
complications in people with type 1 diabetes. The DQOL showed that intensive insulin therapy did not 
impair QoL compared with standard treatment [10]; however, it was also reported that intensified 
treatment was associated with a significant, threefold increase in severe hypoglycaemia. With 
everything that was known about the burden of intensive insulin therapy and severe hypoglycaemia, 
the responsiveness of the DQOL and the validity of the conclusions drawn were called into question 
[11].  
Meanwhile, in the UK, another large-scale landmark trial was also about to conclude. When the UK 
Prospective Diabetes Study (UKPDS) began in the late 1970s, there were no diabetes-specific 
measures of QoL available. So, researchers included a newly developed generic scale: the EQ-5D [12]. 
The EQ-5D has five questions about mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression, and a ‘thermometer’ scale for rating ‘my health today’. The EQ-5D detected 
significant differences between people with and without macrovascular complications (although not 
microvascular complications), but not between people randomized to different treatment regimens 
(intensive vs conventional). Thus, UKPDS researchers concluded that the 'therapies can be given 
according to clinical requirements without undue concern about adverse effects on QoL' [12]. 
However, the EQ-5D was designed to assess general health status not general QoL. In reality, the 
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Those early and prominent attempts to assess the impact of novel diabetes treatment regimens on QoL 
were visionary and commendable. However, they were also met with considerable and well-founded 
critique regarding the operationalization of the concept of QoL, which misled the research and clinical 
communities into thinking that intensive and conventional approaches to diabetes management were 
equivalent in their impact on QoL. With hindsight, it is clear that the EQ-5D, a measure of generic 
health not QoL [12], should not be expected to differentiate two forms of diabetes treatment 
(injections vs tablets). Subsequently, it had been demonstrated that the aspects of life commonly 
considered to be important for QoL include family, friends and work/school, and only a minority 
suggested health as important for QoL, even when they had a significant health condition, such as 
diabetes [6]. While the DCCT researchers designed a questionnaire that focused on the impact of 
diabetes, they took a functional approach. They included a mix of items, whereby some items (e.g. 
worry about ‘getting complications’) might be expected to raise concerns among those allocated to 
standard treatment, while others (e.g. worry about ‘losing consciousness’) might be expected to raise 
concerns among those allocated to intensified treatment. Consequently, examining total scores, rather 
than individual item scores, is likely to have masked the impact of the therapies on QoL [11]. 
Furthermore, the DQOL included many generic items (e.g. ‘how satisfied are you with your sex 
life?’), where an attribution to the impact of diabetes (or its treatment) was not invited [2]. 
 
What has the past 25 years of research shown?  
 Quality of life research in diabetes will realise its full potential  
when [we can] design, implement, and evaluate interventions  
which influence factors that may affect quality of life. 
 (Rubin and Peyrot [13]) 
Confusion about the concept of quality of life 
While QoL has become a buzzword in healthcare research, there is considerable confusion in the 
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example, the Australian Centre for Quality of Life’s directory of instruments includes no fewer than 
1200 measures, each purporting to measure QoL in some form, and each containing a unique mixture 
of dependent variables [14]. Few papers report a detailed rationale for assessment, and then often 
match the wrong measure to the concept of interest, misinterpreting their data as measuring the impact 
of diabetes on QoL when, in reality, they have assessed treatment satisfaction, health status or 
diabetes distress. While these errors were noted in a 2009 review [15], there is little evidence that this 
situation has improved. Further, as Polonsky noted two decades ago [16], researchers and clinicians 
appear to apply one or more of three criteria when attempting to assess the impact of diabetes on QoL. 
They: 1) use whatever has been used in other studies; 2) consider QoL to be an ‘umbrella’ construct 
for psychological health (e.g. depression, well-being) and then use any instrument that appears to 
have reasonable psychometric properties; and 3) use any questionnaire that includes ‘QoL’ in the title 
or has been referred to as ‘QoL’ in a previous paper. 
Second generation measures of diabetes-specific quality of life 
In the mid-late 1990s, recognizing that the DQOL was low on sensitivity and responsiveness, two 
European research groups developed a second generation of diabetes-specific QoL measures: the 
DSQOLS (Diabetes-Specific Quality Of Life Scale) [17] and the ADDQoL (Audit of Diabetes-
Dependent Quality of Life) [18].  
Like the DCCT researchers before them, when designing the DSQOLS [17], Bott et al. took a 
functional approach to explaining specific aspects of diabetes that might impact upon aspects of QoL. 
Designed specifically for people with type 1 diabetes, the DSQOLS included 44 items measuring the 
impact of diabetes on ‘social relations’, ‘leisure time flexibility’, ‘diet restrictions’, ‘physical 
complaints’, ‘daily hassles’, ‘worries about the future’ and a further 20 items measuring treatment 
satisfaction. Like the DQOL, there was a mix of generic and diabetes-specific items (e.g. ‘I feel 
physically ill’, ‘Because of my diabetes my family life is affected’). There was no opportunity for 
respondents to indicate that an aspect of life was ‘not applicable’ or that one aspect of life was of 
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demonstrated the immediate and sustained (up to 1 year) effects of a structured diabetes education 
programme, administered in routine care [20]. 
In their design of the ADDQoL [18], Bradley et al. attempted to remain true to the theory 
underpinning generic QoL research by exploring the impact of diabetes on domains of life important 
to the individual. To generate questionnaire items, they used the Schedule for the Evaluation of 
Individual Quality of Life (SEIQoL) method. This involved undertaking person-centred interviews 
with 12 adults with diabetes to determine the aspects of life important for their QoL and impaired by 
having diabetes. They identified 13 domains: ‘working life’, ‘social life’, ‘family life’, ‘friendships’, 
‘sex life’, ‘holidays and leisure activities’, ‘travel’, ‘worries about own future’, ‘worries about future 
of others’, ‘motivation to achieve things’, ‘physical activities’, ‘others fussing’ and ‘enjoyment of 
food’. The ADDQoL was framed such that respondents were first asked to respond to a statement such 
as: ‘If I did not have diabetes, my [insert domain] would be’ (from ‘very much better’ to ‘very much 
worse’ on a  seven-point scale, with 'not applicable' (N/A) options available for 10 of the 13 items). 
Next, they rated how important each domain was to their overall QoL (from ‘very important’ to ‘not at 
all important’, on a four-point scale). The widespread use of the N/A options (e.g. 44% for 
employment) confirmed the need to offer people the option to indicate when an aspect of life is not 
relevant to them. The wide variation in the importance ratings provided evidence of the need to weight 
QoL domains [18]. Overall, the aspect of life most negatively impacted by diabetes was ‘enjoyment of 
food’, and this was more marked for people with insulin-treated than non-insulin-treated diabetes [18]. 
The validity of this finding was supported elsewhere in the literature [21, 22].  
Despite having a strong conceptual foundation and psychometric properties, the ADDQoL has also 
met with criticism. A key concern is the hypothetical nature of the item wording ('if I did not have 
diabetes…’) [15]. In addition, some argue that weighting items is impractical and uninterpretable, as 
the responses from each individual do not "represent the same ‘true’ level of QoL"[23].  
Recently, the impact of diabetes on key life domains was assessed in the second global Diabetes 
Attitudes Wishes and Needs (DAWN-2) study. The DAWN-2 Impact of Diabetes Questionnaire 
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to produce a brief, comprehensive, and universally relevant measure (i.e. for adults with type 1 or type 
2 diabetes, across cultures), capable of capturing positive or negative impact. In contrast to the >40-
item ADDQoL and DSQOLS, the DIDP measures the perceived impact of diabetes with six items: 
physical health; emotional health; financial situation; leisure; work; and family/social life [24]. 
Known-groups validity has been demonstrated for diabetes type, treatment type, and absence/presence 
of complications and severe hypoglycaemia [25,26], while responsiveness (sensitivity to change) is 
yet to be determined. The DIDP has been used to quantify and benchmark the impact of diabetes on 
people’s lives across different life stages, types of diabetes and cultures, in 17 countries [27]. 
The development of the DIDP domains was informed by extensive previous research on the key life 
domains considered to be important for QoL for people with diabetes, and aligns with several of the 
most discriminatory items included in the ADDQoL [18]. Like the ADDQoL, the DIDP is an 
attributional measure, which means ratings do not reflect the actual level of the life domain but are 
based on the individual’s attribution of the 'perceived impact' of diabetes on the life domain. High 
completion rates support that people with diabetes are able to make meaningful assertions of how 
diabetes impacts on the key life domains using the brief global DIDP items [26]. However, the 
prioritization of brevity may be at the cost of comprehensiveness and specificity. For example, the 
DIDP does not assess life domains shown to be compromised among adults with diabetes, and 
responsive to intervention, such as dietary freedom or independence [26].  
Importance of theoretical underpinnings and rigorous design  
In the past 15 years, the US Food and Drug Administration has provided guidance about the 
documentation required if questionnaires are to be used to support labelling claims for medicinal 
products [28]. If you wish to claim that a certain diabetes treatment improves QoL, then the 
development of the questionnaire will be heavily scrutinized to ensure that it does, indeed, assess 
what is claimed for the particular target population. It is insufficient to demonstrate satisfactory 
psychometric properties alone;  a questionnaire needs to also have satisfactory face and content 
validity. For both the DQOL and the DSQOLS, there is almost no information in the development 
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were not designed carefully (to the standard of their day) but, rather, that there is an absence of 
published evidence. Today, researchers need to answer the following questions, among others: What 
is the conceptual framework for the questionnaire? How were items generated and in which 
populations? To what extent do the items represent the concerns of people with diabetes (rather than 
the perceptions of their clinicians)? To what extent were the items debriefed with people with diabetes 
to determine ease of understanding, ease of completion, comprehensiveness, redundancy and 
omissions?  
Realising the potential of quality-of-life research 
In the late 1990s, a team of UK clinicians had observed that the German Diabetes Teaching and 
Treatment Programme (DTTP) had achieved impressive biomedical outcomes (reducing both HbA1c 
and severe hypoglycaemia, unlike the DCCT) that were sustained over several years [29]. They 
wanted to undertake a UK trial to determine whether similar effects could be achieved. The DTTP 
enabled a flexible intensive insulin regimen, but this had not been emphasized in the German 
descriptions, and its impact on QoL had not been assessed [30]. Meanwhile, emerging UK research 
showed that ‘dietary freedom’ and ‘enjoyment of food’ were the domains of life most negatively 
impaired by type 1 diabetes [17,31]. This suggested that the DTTP may produce QoL benefits, and 
this was counter-intuitive because of the intensive injections and finger-prick monitoring required 
[30]. Thus, the ADDQoL was included in the evaluation with the impact of diabetes on QoL noted as 
a co-primary endpoint. In other words, the trial would not be considered successful unless the 
intervention achieved a reduction in HbA1c and in the negative impact of diabetes on QoL. In the 
UK, the DTTP was renamed ‘Dose Adjustment for Normal Eating’ (DAFNE). The trial demonstrated 
that DAFNE reduced both HbA1c and the negative impact of diabetes on QoL, and also that ‘general 
QoL’ improved [32]. Such findings had never been observed in a diabetes trial. Referring to the 
DAFNE findings, Wolpert and Anderson wrote: 'the tools of intensive diabetes management should 
be presented to the patient as a means of increasing the freedom in their lives rather than simply as a 
means of intensifying glycaemic control' [1]. In the words of Rubin and Peyrot [13], QoL research 
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Where are the current gaps?  
Researchers are striving to address a number of methodological issues in 
their efforts to study quality of life in people with diabetes 
(Rubin & Peyrot [13]) 
Which measure of the impact of diabetes on quality of life should we use? 
The extensive research on the impact of diabetes on QoL during the past 25 years has increased our 
understanding of the complexity of the impacts of diabetes on QoL, and an arsenal of related patient-
reported outcome measures has been developed. It is beyond the remit of this review to provide 
specific recommendations about the best measure to select and, indeed, it is unlikely that any single 
measure will be appropriate in all circumstances. Table 1 distinguishes generic and diabetes-specific 
QoL with increasing specificity, i.e. at the global level, broad domains and specific domains. Table 2 
provides an overview of considerations when selecting a generic or diabetes-specific measure, based 
on conceptual, psychometric and practical considerations. 
Decisions about which measures to use for a particular purpose need to be taken in collaboration with 
people with diabetes and other key stakeholders based on the specific purpose for and context of 
making the assessment. A recent study has examined both the acceptability to people with diabetes 
and the psychometric properties of contemporary diabetes-specific QoL measures. It suggests the 
DIDP is the strongest measure across predetermined criteria, but properties such as responsiveness 
and predictive validity were not assessed in this cross-sectional study [33,34]. A full report will be 
published in due course and these findings need to be corroborated.  
Ongoing measurement challenges 
In the assessment of diabetes-specific QoL, we continue to justify the prioritization of some 
measurement attributes at the cost of others. For instance, the comprehensive ADDQoL and DSQOLS 
include a vast number of items, sacrificing brevity and potentially leading to user (participant and 
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changes in treatment [20], they more accurately assess the related, but distinct, concepts of diabetes 
distress and treatment satisfaction. In contrast, efforts have been made recently to reduce both the 
length and complexity of scales, including only those global dimensions shared by all and foregoing 
importance ratings (e.g. DIDP). However, brief scales potentially ignore important life domains 
identified in both qualitative and quantitative research [18,31]. The question of how many, and which, 
aspects of life needs to be considered in the assessment of quality of life remains unanswered.  
Assessing the impact of diabetes on QoL using standardized measures acts to constrain both the 
assessed and expected ‘impact’.  People with diabetes report difficulty in isolating the impact of 
diabetes, from other life factors, on QoL [34]. For example, while an individual may be able to reflect 
easily and quickly on how satisfied they are with their finances (a generic QoL dimension), it may be 
more difficult to reflect on the impact of their diabetes on their finances (e.g. DIDP), or consider if 
their financial situation would be better if they did not have diabetes (e.g. ADDQoL). With regard to 
response options, both the DIDP and ADDQoL include bi-directional response options, allowing 
either positive or negative responses. However, existing questionnaires do not allow for the possibility 
of a combination of both positive and negative impacts within a single domain. For example, diabetes 
may be perceived to negatively impact on health, but self-care activities since (such as dietary 
changes) may be perceived as having a positive impact on health. Thus, the respondent is required to 
average out the direction of the perceived impact in their response. 
Populations with little evidence 
Views about QoL and what it means vary naturally across the lifespan and across cultures. For this 
reason, it is vital that QoL measures are developmentally and culturally appropriate. The DAWN-2 
study is one of the few that has compared the impact of diabetes across countries and cultures, with 
large variations identified [27]. This suggests that further work is needed to explain these findings and 
determine ways to minimize the variation.  
In comparison with adults, we know less about the impact of diabetes on the QoL of children, 
adolescents, younger adults and older adults. It is clear that what matters for a child’s or adolescent’s 
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will change with age [35–37]. A systematic review of 17 studies examining QoL in children and 
adolescents with type 1 diabetes showed that generic QoL was no different from that of peers without 
diabetes, but that diabetes-specific impacts, e.g. on daily functioning and emotional well-being, were 
present [38]. In addition, young adults (with type 1 or type 2 diabetes) are specific sub-populations 
that may require modification of existing tools or development of new ones, as neither the paediatric 
nor adult measures may serve them well enough. Few studies are focused on older populations who 
have the highest prevalence of diabetes and are the fastest-growing section of the population [39]. 
Easy-to-use formats and enlarged fonts are critical when asking older adults to complete 
questionnaires [40]. The ADDQoL Senior [41] was developed taking into account formatting and age-
specific changes to the domains of life assessed. This has shown that the greatest impact of diabetes is 
on ‘independence’ and ‘freedom to eat as I wish’. 
Finally, there is a need to design and harmonize measurement frameworks to ensure that the diabetes-
specific QoL for research and clinical purposes, through systematic collaboration with people with 
diabetes, carers and multi-stakeholder expert groups. 
 
Translation/implementation  
QoL is such a subjective evaluation and so specific to the individual…  
that there is no substitute for asking patients what is important to them, how 
good these things are in their life and  
how the elements of their life affect each other and their overall QoL  
(Walker and Bradley [37])  
Quality of life is recognized as an important outcome in its own right but it is rarely assessed (well) in 
diabetes research and clinical practice. However, when the only outcomes measured by health 
professionals, systems and policy makers are biomedical (e.g. HbA1c, lipids), interventions to support 
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In clinical trials, the impact of new diabetes treatments/technologies on QoL has been reasonably well 
evaluated, but this could be more consistent and there are many instances where inappropriate tools 
have been used or their data misinterpreted as QoL [15]. There is a need for harmonization of 
measurement of the impact of new treatments/technologies on QoL in clinical trials; however, there 
remains no consensus or standards for which tools to use. An important recent development is the 
consensus on core patient-reported outcomes relevant for particular purposes in diabetes. The global 
International Consortium for Health Outcomes Measurement (ICHOM) diabetes standard set [43] 
includes: the WHO-5 (general emotional well-being), the Problem Areas in Diabetes (PAID; diabetes 
distress), and the Patient Health Questionnaire (PHQ-9; depressive symptoms). The recommendations 
to measure the outcomes of diabetes using these three measures were based on: 1) a consensus that 
the measures assess core outcomes established as important to people with diabetes, so-called 
‘patient-important’ measures; and 2) pragmatic criteria of their broad scientific validation, multiple 
language versions, and being freely available. However, these strengths do not negate that the 
measures do not provide a theoretically grounded or comprehensive assessment of the impact of 
diabetes on a person’s QoL.  
In terms of the assessment of QoL in clinical diabetes care, progress has been made to integrate 
assessment of psychological well-being as an indicator of QoL, but more work is needed. In October 
1989, the St Vincent Declaration set out several general goals for people with diabetes, including: 
'sustained improvement in health experience and a life approaching normal expectation in quality and 
quantity' [44]. Thus, there was a goal of achieving QoL but, at that time, limited options for 
measuring it. The WHO’s response included the DiabCare Quality of Care Monitoring Programme, 
which recommended assessments of general well-being and satisfaction with diabetes treatment [45]. 
Over the past two decades, increasing numbers of (inter)national guidelines have recommended 
routine monitoring of mental health and/or psychosocial aspects of diabetes, with the aim of 
improving integration of these factors in the individual’s clinical care planning [46]. Studies have 
shown that using validated psychological measures and discussing the outcomes is feasible, 
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recommendations to assess diabetes-specific QoL in clinical practice. As noted earlier, QoL is a 
multidimensional, subjective and dynamic construct, which may be difficult to capture 
comprehensively in a standardized tool in the clinical setting. Clinicians are asking psychologists for a 
short QoL measure that is easy to use in their diabetes clinics, but are we in a position to recommend 
a QoL measure for use in clinical practice? Although such a questionnaire may provide a standardized 
approach to monitoring and enable assessment of change over time, asking open-ended questions is 
an important alternative approach for routine practice. It provides the person with diabetes the 
opportunity to raise any aspect of their life that they consider highly important and to discuss how 
diabetes and/or its treatment is affecting it.  
 
The Path Forward 
This review has identified a significant unmet need for adopting a systematic and methodological 
approach to the assessment of the impact of diabetes on QoL in research and clinical care. In many 
ways, the opportunities and challenges we faced in 1995 in assessing the impact of diabetes on QoL 
remain, and they are both conceptual and practical. How do we assess comprehensively the full and 
individualized impact of diabetes on QoL while balancing this against respondent burden and 
generalizability? How can respondents reliably isolate the impact of their diabetes from that of other 
health issues or life in general? How can we assess both negative and positive impacts of diabetes, 
potentially even within the same life area (e.g. health)? These questions have led to the development 
of a range of measures. But are we any closer to a measure that answers all these questions? Or do we 
need to prioritize certain strengths/limitations of our approach based on the setting or population? 
There is a need for the field to revisit the core concept of QoL and ensure it is operationalized 
appropriately, using the ‘best practice’ principles for developing new questionnaire measures. 
Furthermore, QoL research has shown that understanding and exploring QoL can reveal motivating 
factors that are relevant in everyday clinical care. For example, if dietary freedom is important, the 
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independence is important, then the person may be motivated to prioritize their eye health and to 
undertake the behaviours needed to achieve this. Eilander et al. [48] implemented a QoL monitoring 
intervention in 11 Dutch paediatric diabetes clinics: surveys after implementation showed 67% of 
healthcare professionals believed that discussing QoL contributed to adolescents’ health and 92% felt 
the tool had additional value to routine care; 85% of adolescents felt they were ‘heard’, but clinics 
struggled with logistics, such as time, staffing and workflow design. This highlights that clinical 
guidelines are a necessary step forward but that it is equally important to allocate resources to 
resolving how to implement the guidelines and provide psychological care following the assessment 
[49], improving models of care by learning from best practice [50].   
 
Conclusion  
Despite the importance of QoL (‘a life worth living’), we appear to be somewhat paralysed by the 
complexity of the rigorous assessment of diabetes-specific QoL (both conceptually and 
methodologically). The reality remains that the impact of diabetes on QoL is not systematically 
assessed in research or, for the vast majority of people with diabetes, in clinical care, although 
international initiatives such as ICHOM highlight the importance of this field and enable progress to 
be made. There are huge benefits of including its assessment in our approach to diabetes care. As 
Wolpert and Anderson [1] stated, 'focusing on the immediate lifestyle benefits can be critical to 
overcoming patients’ ambivalence about change and promoting engagement in self-care'. Recent 
studies show that people with diabetes value these assessments, and we know more about the key 
barriers to the routine assessment, and the importance of the maturation of IT health systems and 
resources for person-centred care, which ensures adequate follow-up can be made in response to QoL 
findings. However, it remains that clinicians, and the health systems that reimburse them, need to 
prioritize QoL as being at least as important as biomedical markers of health if QoL research is to 
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Table 1  Differentiating generic and diabetes-specific quality of life with increasing 
specificity of domains 
 
Sample wording for item and response 
Generic QoL 
(no attribution; may be 
influenced by other health 
problems or issues in life) 
Diabetes-specific QoL 







e.g. 'How is your QoL?'    
'extremely good – extremely bad' 
e.g. 'How is your diabetes 
affecting your QoL?'          
'extremely positive impact – 







aspects of life 
e.g. 'How is your social life?' 
'extremely good – extremely bad' 
e.g. 'What is the impact of 
diabetes on your social life?' 
'extremely positive impact – 











e.g. 'How are your relationships 
with family/ friends?'                             
'extremely good – extremely bad' 
e.g. 'How does diabetes impact on 
your relationship with 
family/friends?'           'extremely 
positive impact – extremely 
negative impact' 
QoL, quality of life. 
*Numerous domains that may be considered important for QoL at this level. It is important to note 
that such domains need to be relevant to the general population in order to be considered ‘QoL’ 
domains. For example, an item about the extent to which your diabetes treatment regimen is causing 
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Table 2  Questions to consider when selecting generic and diabetes-specific measures to assess the impact of diabetes on quality of life 
 Generic measures Diabetes-specific measures 
What is your purpose in using the 
measure?  
Consider the target condition group, 
population, intervention, and setting. 
May be useful when comparing the outcomes of 
people with diabetes with other populations and are 
important for the calculation of QALYs.  
 
May be useful when comparing diabetes 
treatments/technologies or when specifically interested 
in the attribution of how diabetes is affecting a 
person’s life. 
Does the measure have good face 
validity?  
Face validity can be assessed by 
looking over the instrument and 
considering each item (and its response 
options) individually. Consider 
whether the content is relevant and if 
any relevant issues are missing. 
Tend to include items about self-care or ability to 
walk, which may not be relevant to populations with 
fewer or less advanced diabetes-related complications 
(e.g. younger people or those with a shorter duration of 
diabetes). Conversely, these measures often exclude 
items, such as dietary freedom, demonstrated to be an 
important issue for QoL in people with diabetes. Such 
omissions may mean that the full impact of diabetes is 
not assessed and potentially significant treatment 
benefits may not be demonstrated. Consequently, 
generic measures may not be useful when comparing 
Likely to appear to be more relevant due to the 
attribution to diabetes and the inclusion of issues 
relevant to living with diabetes. However, it remains 
important to check item content and ensure that items 
that may be important for the population’s or 
individual’s QoL and/or affected by the intervention 
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 Generic measures Diabetes-specific measures 
two long-acting insulins, two glucose monitoring 
devices or two structured education programmes. 
Does the instrument have good 
content validity?  
Has the instrument been developed for 
the purpose for which you will use it 
and with the population who will 
complete it? For example, is there 
evidence of qualitative research with 
the target population underpinning the 
design of the measure? 
May have good content validity in the general 
population but may not be entirely suitable for people 
with diabetes, e.g. because they exclude issues of 
relevance or place too much emphasis on issues that 
are not relevant (see above for examples). 
Take care to ensure that the measure has been designed 
for your specific population (e.g. adolescents versus 
older adults with type 1 diabetes, different diabetes 
types). Different or additional content may be required. 
Will the measure be acceptable to 
respondents?  
Generic instruments may lack face validity for people 
with diabetes if too many items seem irrelevant to their 
situation, to the impact of the intervention or simply 
because the questionnaire, as whole, does not refer to 
the impact of diabetes. 
Some diabetes-specific measures may include sensitive 
issues (e.g. impact of diabetes on romantic 
relationships and intimacy) which may affect their 
acceptability. Questionnaire complexity and length 
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 Generic measures Diabetes-specific measures 
population is 1) elderly or very young, and/or 2) has 
low literacy levels. 
What is the burden on respondents? 
This is particularly relevant in clinical 
care and when other measures will 
need to be included in studies with a 
broad remit. 
As above, generic instruments may lack face validity 
for people with diabetes and increase the perceived 
burden of completing the questionnaires. 
Typically, people are more willing to complete 
questionnaires that they perceive to be relevant to their 
condition and personal situation, and easy to complete 
(i.e. not complex or confusing). 
Will responses be influenced by 
other conditions⁄ factors?  
Generic measures are particularly susceptible to the 
impact of other conditions as there is no attribution to 
diabetes required or desired. For example, comorbid 
conditions are likely to affect responses to generic 
measures. Consequently, generic measures need 
careful and appropriate interpretation. 
Diabetes-specific measures typically include an 
attribution to diabetes (although there are exceptions at 
an item level), minimizing the possibility of influence 
by other conditions/factors. Conversely, it can 
sometimes be difficult for people with diabetes to 
isolate the impact of diabetes (e.g. on their mood or 
their leisure time) from other factors, particularly if 
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 Generic measures Diabetes-specific measures 
Has the measure been validated in 
the target population? Consider 
diabetes type/treatment, age group, 
country, and language?  
In many cases, generic measures are likely to be 
available in multiple language versions. This is a 
pragmatic reason for selecting a generic over a 
diabetes-specific measure. 
Several diabetes-specific QoL measures are available 
in multiple language versions. 
 
QALY, quality-adjusted life year; QoL, quality of life. 
  
